@kartc @ABsteward @pranita_tamma @davidvanduin @ClancyNeil @IDSAInfo @IDstewardship @InfectiousDz @DrToddLee @BradSpellberg @Josh_S_Davis @jasonroberts_pk The one RCT of cefepime for UTI caused by ESBL producers was stopped early due to increased failure r
@DocWoc71 @davidvanduin @ARLetourneau @IDJClub @IDSAInfo @ClancyNeil This RCT suggest that even for UTI, cefepime underperforms carbapenems https://t.co/2P6CE0kwwR there are observational data pointing in the opposite direction and I think it is a viable s
@ARLetourneau @IDJClub This is very interesting and new to me. Do you know if there is evidence to show cefepime with MIC<2 can be used to treat ESBL? Thank you. https://t.co/uxlWnHVHgE
@OncIDPharmd @DrToddLee @ABsteward @pranita_tamma @jesusrbano @MerinoTrial @padstamundo @ClancyNeil What do you make of this very small RCT in UTI with systemic signs suggesting pyelo which found pip/tazo to be non-inferior to erta? https://t.co/skyQeJQEc8
@emilylheil @OncIDPharmd @SIDPharm MERINO was that convincing to you? https://t.co/skyQeJQEc8
@DHpharmd @OncIDPharmd @ChristianCho @SIDPharm @IDSAInfo @IDWeek2018 @accpinfdprn There is a small RCT specifically in UTI that demonstrated similar outcomes with pip/tazo and erta, and 20-30% of those had bacteremia. https://t.co/skyQeJQEc8
Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spec... - PubMed - NCBI https://t.co/fhpy2rQ8zA
@TiffenyTSmith @BradSpellberg @IDstewardship @IDSAInfo @SIDPharm @accpinfdprn @accpcritprn @SICUPharmD @jpogue1 @JGPharmD @khalideljaaly @mmPharmD Cefepime failed pretty remarkably even in this RCT in ESBL UTIs...agree with avoiding it for most cases. http
@davidvanduin @davidantibiotic @idfactoid @MerinoTrial Also this RCT of ESBL UTI where the cefepime arm was stopped early for futility. https://t.co/skyQeJQEc8
@ASP_PharmD If it's a low MIC and mild disease, you may be ok, but I would be cautious. https://t.co/skyQeJQEc8
@Saudi_Pharma A study compare PTZ , Ertapenem and Cefepime against E. coli ESBL .. the cefepime group stooped due to haigh failure number https://t.co/1iqP4WBgVH
RT @khalideljaaly: @ABXPharmD @accpinfdprn Thanks much for sharing. Well, seems it is concerning even for UTI. Check out this recent one: h…
Interesting start- looking forward to the larger Pip-tazo vs. mero bacteraemia study results @padstamundo https://t.co/W0W9Viihou
Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract… https://t.co/tUbU3rTtvI
Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment o... https://t.co/Pw9BYPddck #bmcinfectdis
RT @kadsho: 初期治療CFPMでESBL判明時にそのままで挑むのはやめた方がよさそう。 セファマイシン(CMZ、FMOX、LMOX)はどうなんでしょうかね? https://t.co/5kNRjwYmOS
RT @jichisaitamaicu: https://t.co/4midwjoUgf BMC Infect Dis。ESBL産生大腸菌による尿路感染に対してPIPC/TAZ、CFPM、ertapenemの効果をみたRCT。PIPC/TAZとertapenemは共に90%台の…
RT @kadsho: 初期治療CFPMでESBL判明時にそのままで挑むのはやめた方がよさそう。 セファマイシン(CMZ、FMOX、LMOX)はどうなんでしょうかね? https://t.co/5kNRjwYmOS
RT @jichisaitamaicu: https://t.co/4midwjoUgf BMC Infect Dis。ESBL産生大腸菌による尿路感染に対してPIPC/TAZ、CFPM、ertapenemの効果をみたRCT。PIPC/TAZとertapenemは共に90%台の…
https://t.co/4midwjoUgf BMC Infect Dis。ESBL産生大腸菌による尿路感染に対してPIPC/TAZ、CFPM、ertapenemの効果をみたRCT。PIPC/TAZとertapenemは共に90%台の奏効率だが、CFPMは30%台で6例で終了。
RT @AMRCRC_JAPAN: ESBL産生菌による尿路感染症は、ピペラシリン・タゾバクタムでもエルタペネムと同等に高い治療成功率。セフェピムは治療失敗率が高い(韓国はエルタペネムあるんですね)。 https://t.co/ThnY2x9oXu
RT @AMRCRC_JAPAN: ESBL産生菌による尿路感染症は、ピペラシリン・タゾバクタムでもエルタペネムと同等に高い治療成功率。セフェピムは治療失敗率が高い(韓国はエルタペネムあるんですね)。 https://t.co/ThnY2x9oXu
RT @AMRCRC_JAPAN: ESBL産生菌による尿路感染症は、ピペラシリン・タゾバクタムでもエルタペネムと同等に高い治療成功率。セフェピムは治療失敗率が高い(韓国はエルタペネムあるんですね)。 https://t.co/ThnY2x9oXu
RT @AMRCRC_JAPAN: ESBL産生菌による尿路感染症は、ピペラシリン・タゾバクタムでもエルタペネムと同等に高い治療成功率。セフェピムは治療失敗率が高い(韓国はエルタペネムあるんですね)。 https://t.co/ThnY2x9oXu
RT @AMRCRC_JAPAN: ESBL産生菌による尿路感染症は、ピペラシリン・タゾバクタムでもエルタペネムと同等に高い治療成功率。セフェピムは治療失敗率が高い(韓国はエルタペネムあるんですね)。 https://t.co/ThnY2x9oXu
ESBL産生菌による尿路感染症は、ピペラシリン・タゾバクタムでもエルタペネムと同等に高い治療成功率。セフェピムは治療失敗率が高い(韓国はエルタペネムあるんですね)。 https://t.co/ThnY2x9oXu